Floatz Rating
B62/100
Confidence
Indicative
Sponsor
University of Miami
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06412120CT.gov Study Evaluating Safety, Tolerability, and Metabolism of Niraparib | — | Recruiting | — | — | — |
NCT07059676CT.gov Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer | — | Not Yet Recruiting | — | — | — |
NCT06915025CT.gov Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer | — | Recruiting | — | — | — |
NCT06180356CT.gov Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression | — | Recruiting | — | — | — |
NCT06433219CT.gov Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | — | Active Not Recruiting | — | — | — |
NCT06594679CT.gov A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) | — | Recruiting | — | — | — |
NCT06614790CT.gov Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study. | — | Recruiting | — | — | — |
NCT05990192CT.gov SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy | — | Recruiting | — | — | — |
NCT06161493CT.gov ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors | — | Withdrawn | — | — | — |
NCT05126342CT.gov Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi | — | Withdrawn | — | — | — |
Show 42 more trialsShow fewer
NCT05961124CT.gov Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | — | Recruiting | — | — | — |
NCT04149145CT.gov Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer | — | Withdrawn | — | — | — |
NCT05065021CT.gov Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | — | Unknown | — | — | — |
NCT05238831CT.gov SMMART Adaptive Clinical Treatment (ACT) Trial | — | Withdrawn | — | — | — |
NCT05641506CT.gov A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer | — | Unknown | — | — | — |
NCT05009082CT.gov Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer | — | Recruiting | — | — | — |
NCT05335993CT.gov A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | — | Active Not Recruiting | — | — | — |
NCT05311579CT.gov Niraparib Plus Anlotinib for Recurrent Ovarian Cancer | — | Unknown | — | — | — |
NCT05183984CT.gov Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer | — | Recruiting | — | — | — |
NCT05198804CT.gov A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | — | Completed | — | — | — |
NCT05187208CT.gov PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer | — | Unknown | — | — | — |
NCT04673448CT.gov Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | — | Active Not Recruiting | — | — | — |
NCT05021562CT.gov A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice | — | Completed | — | — | — |
NCT04734665CT.gov Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor | — | Unknown | — | — | — |
NCT04507841CT.gov Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT04679064CT.gov Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment | — | Unknown | — | — | — |
NCT04826198CT.gov Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months | — | Terminated | — | — | — |
NCT04502602CT.gov Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT04392102CT.gov A Study of Niraparib in Patients With Relapsed Ovarian Cancer | — | Completed | — | — | — |
NCT04376073CT.gov Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer | — | Unknown | — | — | — |
NCT04217798CT.gov Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer | — | Unknown | — | — | — |
NCT04284852CT.gov Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting | — | Completed | — | — | — |
NCT04267939CT.gov ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer | — | Terminated | — | — | — |
NCT03806049CT.gov Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | — | Withdrawn | — | — | — |
NCT03891576CT.gov Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer) | — | Terminated | — | — | — |
NCT03983226CT.gov Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) | — | Recruiting | — | — | — |
NCT03752216CT.gov NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. | — | Completed | — | — | — |
NCT03895788CT.gov A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer | — | Unknown | — | — | — |
NCT03695380CT.gov A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer | — | Completed | — | — | — |
NCT03759587CT.gov Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer | — | Completed | — | — | — |
NCT03759600CT.gov Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer | — | Completed | — | — | — |
NCT03783949CT.gov European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | — | Completed | — | — | — |
NCT03709316CT.gov A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer | — | Unknown | — | — | — |
NCT03551171CT.gov The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer | — | Completed | — | — | — |
NCT04785716CT.gov Real-life Use of Niraparib in a Patient Access Program in Norway | — | Completed | — | — | — |
NCT03154281CT.gov Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast | — | Completed | — | — | — |
NCT03705156CT.gov Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient | — | Unknown | — | — | — |
NCT02657889CT.gov Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | — | Completed | — | — | — |
NCT02354586CT.gov A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens | — | Completed | — | — | — |
NCT02354131CT.gov Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer | — | Completed | — | — | — |
NCT01227941CT.gov MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) | — | Terminated | — | — | — |
NCT03025867CT.gov Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Niraparib (this asset) | University of Miami | Approved | B · 62 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| TIL | Inge Marie Svane | P2 | BB |
| Olaparib | Shandong University | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Kalinski, Pawel, MD, PhD | P3 | BB |
| Adriamycin | Genmab | P3 | BB |
| Carboplatin | Fudan University | P4 | BB |
| OTL-38 | On Target Laboratories, LLC | P4 | BB |
| Irinotecan | ARCAGY/ GINECO GROUP | P4 | BB |
+42 more in the Ovarian Cancer cohort
Other indications for Niraparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BB · 67 |
| Ovarian Carcinoma | — | P4 | BB · 66 |
| Ovarian Neoplasm | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Niraparib in Ovarian Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/niraparib-ovarian-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →